Floatz logo

Tsc-201-B0702

HPV Positive Oropharyngeal Squamous Cell Carcinoma

TScan Therapeutics, Inc.Cell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the HPV Positive Oropharyngeal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Cetuximab
National Cancer Institute (NCI)
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 2CCC
had5-hpv vaccine
ImmunityBio, Inc.
Phase 2CCC

View all 31 →

Same molecule, other indications

Tsc-201-B0702 is also rated in:

anogenital human papillomavirus infectionDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cervical carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →